Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers -April 11, 2024 at 08:05 am EDT

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.Tevogen Bio plans to...

Related Keywords

Tevogen Bio ,Tevogen Exactcell ,Neal Flomenberg ,Tevogen Bio Communications ,Tevogen Bio Holdings Nasdaq ,Tevogen Bio Holdings ,Chief Scientific Officer ,Human Papilloma Virus ,Semper Paratus Acquisition Corporation ,Business Combination ,Markets ,